Sanofi to Develop Biomunex Bi-, Multi-Specific Antibodies for Immuno-Oncology and Other Areas

Sanofi to Develop Biomunex Bi-, Multi-Specific Antibodies for Immuno-Oncology and Other Areas

Doubling Down on Gene Therapies, Novartis Buys CellforCure to Manufacture CAR-T Products

Doubling Down on Gene Therapies, Novartis Buys CellforCure to Manufacture CAR-T Products

Merck takes a back seat on CAR-T, handing assets to Intrexon

Merck takes a back seat on CAR-T, handing assets to Intrexon

LYNPARZA® (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer

LYNPARZA® (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-mutated Advanced Ovarian Cancer